Gain Interest Debt Per Share from 2010 to 2024

GANX Stock  USD 1.74  0.01  0.58%   
Gain Therapeutics Interest Debt Per Share yearly trend continues to be fairly stable with very little volatility. Interest Debt Per Share is likely to outpace its year average in 2024. During the period from 2010 to 2024, Gain Therapeutics Interest Debt Per Share regression line of annual values had r-squared of  0.60 and arithmetic mean of  0.12. View All Fundamentals
 
Interest Debt Per Share  
First Reported
2010-12-31
Previous Quarter
0.04364263
Current Value
0.077
Quarterly Volatility
0.06240989
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 150 K, Net Interest Income of 579.3 K or Depreciation And Amortization of 44.3 K, as well as many indicators such as Price To Sales Ratio of 733, Dividend Yield of 0.0 or PTB Ratio of 3.55. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Gain Therapeutics Correlation against competitors.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Latest Gain Therapeutics' Interest Debt Per Share Growth Pattern

Below is the plot of the Interest Debt Per Share of Gain Therapeutics over the last few years. It is Gain Therapeutics' Interest Debt Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Gain Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Interest Debt Per Share10 Years Trend
Slightly volatile
   Interest Debt Per Share   
       Timeline  

Gain Interest Debt Per Share Regression Statistics

Arithmetic Mean0.12
Geometric Mean0.09
Coefficient Of Variation50.02
Mean Deviation0.06
Median0.17
Standard Deviation0.06
Sample Variance0
Range0.1701
R-Value(0.78)
Mean Square Error0
R-Squared0.60
Significance0.0007
Slope(0.01)
Total Sum of Squares0.05

Gain Interest Debt Per Share History

2024 0.077
2023 0.0436
2022 0.0508
2021 0.0899
2020 0.0622
2019 0.001729

About Gain Therapeutics Financial Statements

Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' Interest Debt Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Interest Debt Per Share 0.04  0.08 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.